Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity
A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference.
Richard Tangtwo-minute read
Eli Lilly+1.44% — Eli Lilly, up 1.44 percent today said Monday that Foundayo, its once-daily obesity pill, significantly cut the severity of obstructive sleep apnea in a Phase 3 trial, and the company committed to file with the FDA for that use by the end of 2026 1. The result moves the pill toward a diagnosed disease with its own spending, away from weight-loss benefits that insurers have been trimming. Lilly's shares rose about 3% on the news as Jefferies−2.31% — Jefferies, down 2.31 percent as of its last quote set a street-high $1,700 price target 3.
Why a sleep apnea label changes who pays
Obstructive sleep apnea is interrupted breathing during sleep, when the airway narrows or collapses; it affects an estimated 936 million adults worldwide, most never diagnosed, and is linked to hypertension, heart failure and stroke 1. The mechanism runs through weight: patients in Lilly's ATTAIN-OSA trial lost about 11% of their body weight, and the airway collapses less when the fat around it shrinks 12.
Foundayo is a GLP-1, the drug class behind Ozempic, Wegovy and Zepbound, and reduced breathing interruptions per hour, the standard severity measure, by 43.8% in patients not using a CPAP machine, against 6.3% on placebo; roughly a third of that group reached remission or mild disease 12.
Foundayo cut breathing interruptions 43.8% where placebo managed 6.3%
The pill cut severity far more than placebo in patients not on CPAP
Data
| Value | |
|---|---|
| Foundayo, no CPAP | -43.8% |
| Placebo, no CPAP | -6.3% |
| Foundayo, on CPAP | -27.5% |
| Placebo, on CPAP | -3% |
Payers fund drugs for diagnosed diseases out of a medical budget; weight-loss prescriptions fall under a benefit many insurers have been cutting. Zepbound, Lilly's injection, won the first FDA approval for sleep apnea in December 2024, and Foundayo would be Lilly's second drug for the same condition 6. The edge over Novo Nordisk's−1.56% — Novo Nordisk, down 1.56 percent today own oral Wegovy, as Barron's frames it, is this label breadth 6.
Novo's rival strategy failed at the same conference
At the same American Heart Association meeting, Novo Nordisk's ziltivekimab cut the inflammation marker IL-6 by 76% across 6,376 patients and produced a hazard ratio of 0.99 for heart attacks and strokes, essentially nothing 4. Novo halted two follow-up trials for futility and wrote the drug down in its third quarter 4. Lilly is stacking disease labels instead of betting on outcomes evidence.
The risk numbers a payer reads first
Adverse-event discontinuations ran 12.2% versus 3.8% on placebo among patients not using CPAP, the number payers will read first 1. The FDA this week also required a vision-loss warning across GLP-1 labels, including Lilly's and Novo's 5.
The FDA decision is the easy part; whether insurers pay is what decides the market. A year-end submission is near-certain and priced, but the label only converts into revenue if insurers treat sleep apnea as a covered indication. That decision likely lands over 2027, when payers set their benefit designs.
Get Health by email, free
AI in medicine, pharma and biotech. In our daily email, every weekday.
